1. Home
  2. CAPR vs CIX Comparison

CAPR vs CIX Comparison

Compare CAPR & CIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • CIX
  • Stock Information
  • Founded
  • CAPR 2005
  • CIX 1993
  • Country
  • CAPR United States
  • CIX United States
  • Employees
  • CAPR N/A
  • CIX N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • CIX Industrial Machinery/Components
  • Sector
  • CAPR Health Care
  • CIX Consumer Discretionary
  • Exchange
  • CAPR Nasdaq
  • CIX Nasdaq
  • Market Cap
  • CAPR 324.6M
  • CIX 301.8M
  • IPO Year
  • CAPR N/A
  • CIX 1998
  • Fundamental
  • Price
  • CAPR $6.36
  • CIX $22.93
  • Analyst Decision
  • CAPR Strong Buy
  • CIX
  • Analyst Count
  • CAPR 8
  • CIX 0
  • Target Price
  • CAPR $24.75
  • CIX N/A
  • AVG Volume (30 Days)
  • CAPR 1.2M
  • CIX 9.5K
  • Earning Date
  • CAPR 11-12-2025
  • CIX 11-05-2025
  • Dividend Yield
  • CAPR N/A
  • CIX 5.03%
  • EPS Growth
  • CAPR N/A
  • CIX N/A
  • EPS
  • CAPR N/A
  • CIX 1.51
  • Revenue
  • CAPR $13,392,150.00
  • CIX $152,721,000.00
  • Revenue This Year
  • CAPR N/A
  • CIX N/A
  • Revenue Next Year
  • CAPR $6,061.53
  • CIX N/A
  • P/E Ratio
  • CAPR N/A
  • CIX $15.59
  • Revenue Growth
  • CAPR N/A
  • CIX N/A
  • 52 Week Low
  • CAPR $4.05
  • CIX $17.89
  • 52 Week High
  • CAPR $23.40
  • CIX $33.40
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 42.32
  • CIX 37.59
  • Support Level
  • CAPR $6.05
  • CIX $24.26
  • Resistance Level
  • CAPR $6.62
  • CIX $23.51
  • Average True Range (ATR)
  • CAPR 0.39
  • CIX 0.65
  • MACD
  • CAPR 0.05
  • CIX -0.30
  • Stochastic Oscillator
  • CAPR 47.89
  • CIX 2.82

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About CIX CompX International Inc.

Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.

Share on Social Networks: